
Myeloma Doc @UCSF Focused on CAR-T, bispecifics & high-risk myeloma/EMD Views are my own
- Tweets39
- Following83
- Followers101
- Likes239

ALT Our strategy to address relapse after BCMA CAR T-cell therapy depends on whether a patient has rapid aggressive relapse (i.e., extramedullary disease, plasma cell leukemia, or rapidly rising myeloma markers or disease burden) or biochemical/clinical relapse without aggressive features. For all patients, talquetamab or another GPRC5D bispecific is a preferred approach. For rapid aggressive relapse, high dose cytotoxic chemotherapy or salvage autologous stem cell transplant may also be considered. For other relapses, a retrial of BCMA targeted therapy or various proteasome inhibitor and immunomodulatory drug combinations can be considered. The rapidly changing landscape of available drugs means that several novel approaches or clinical trials may also be available for patients.


























